developing medication assisted treatment (mat) protocols
DESCRIPTION
DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS. Presented by: Andrew J. Saxon, MD July 17, 2013. Objectives:. Consider some of the prior medication assisted treatment protocols conducted in the CTN for lessons learned. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/1.jpg)
2013 CTN Web Seminar Series
Produced by: NIDA CTN CCC Training Office"This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse,
National Institutes of Health, Department of Health and Human Services, under Contract No.HHSN271201000024C."
DEVELOPING MEDICATION ASSISTED TREATMENT (MAT)
PROTOCOLSPresented by:
Andrew J. Saxon, MD
July 17, 2013
![Page 2: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/2.jpg)
2
Objectives:• Consider some of the prior medication assisted
treatment protocols conducted in the CTN for lessons learned.
• Identify design decisions that need to be made concerning medication assisted treatment protocols, including considerations about blinding and adherence strategies.
• Describe regulatory aspects of medication assisted treatment protocols.
![Page 3: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/3.jpg)
3
Trial
Med Treatment
Drug Product
Placebo
Treatment as usual
DESIGNING MEDICATION ASSISTED PROTOCOLS
![Page 4: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/4.jpg)
4
Specific Topics to Consider• Investigational New Drug Application (NDA) from
FDA?• Open label or blinded MAT trial?• Placebo or active comparator?• Dosing strategy—Fixed or flexible?• Adherence strategy?• More exclusive or more inclusive enrollment
criteria?• What, if any, behavioral platform?• Safety monitoring plan
![Page 5: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/5.jpg)
5
REGULATORY CONSIDERATIONS
![Page 6: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/6.jpg)
6
IND• An Investigator IND is submitted by a physician
who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.
![Page 7: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/7.jpg)
7
IND• CDER's
Pre-Investigational New Drug Application (IND) Consultation Program5 fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission. The review divisions are organized generally along therapeutic class and can each be contacted using the designated Pre-IND Consultation List (PDF - 19KB)6.
![Page 8: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/8.jpg)
8
IND Examples• Injectable risperidone for methamphetamine
dependence– Drug company sponsor – wanted IND– Use in new population – FDA requested IND
• Prazosin for Alcohol Dependence– University/NIH sponsor – no position on IND– Given widespread use of prazosin, has probably been
used by patients with AUD– No plans to seek a change in labeling or advertising– Exempt from IND
![Page 9: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/9.jpg)
9
Controlled Substances
• Obtain appropriate DEA licensure
• Obtain licensure specific to each state
![Page 10: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/10.jpg)
10
BLINDING AND PLACEBO STRATEGIES
![Page 11: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/11.jpg)
11
Open Label vs. Blinded Study
Enck et al., 2013
![Page 12: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/12.jpg)
12
Open Label Advantages• Good for pilot studies to test:
– tolerability– safety– possibly dose effects
• More real world• For some medications expectancies are
component of efficacy– Disulfiram (Antabuse)
• Less complex/costly
![Page 13: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/13.jpg)
13
Blinding Advantage• Accounts for expectancy effects
– Patients– Research staff
• Double blind vs. single blind
![Page 14: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/14.jpg)
Benedetti et al., 2005
![Page 15: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/15.jpg)
15
Placebo Response
Benedetti et al., 2005
![Page 16: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/16.jpg)
16
Placebo vs. Active Comparator• If active medication has profound, observable
effects, inert placebo may break blind
• Active “placebo” possible
• If an already approved medication for indication exists, head to head comparison informative
![Page 17: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/17.jpg)
17
PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS
Lessons Learned in the CTN
![Page 18: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/18.jpg)
18
START Study Schema1920 Number screened for participation
1269 Randomized
740 Buprenorphine/Naloxone 529 Methadone
340 Evaluable400 Failed to remain on assigned
medication for 24 wks0 Failed to provide ≥ 4 LT
samples
391 Evaluable 136 Failed to remain on assigned
medication for 24 wks2 Failed to provide ≥ 4 LT samples
261 Completed 32-week follow-up 330 Completed 32-week follow-up
![Page 19: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/19.jpg)
19
CTN 0028 OROS-Methylphenidate ADHD/SUD
Riggs et al., 2011
Titrated to 72 mg per day
![Page 20: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/20.jpg)
CTN 0048 CURB Study Schema
20
![Page 21: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/21.jpg)
21
Fixed vs. Flexible Dosing• Fixed dosing
– requires less physician time– Fixed dosing may miss optimum dose
• Flexible dosing– Titrate to effects/side effects– Need algorithm to guide study physician– More real world– More complex analytic approach may be needed
![Page 22: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/22.jpg)
22
CTN 0003 Buprenorphine TaperTaper Group Total
7 day taper 28 day taper
Stabilization Dose
8 mg 22 26 48 (9.3%)
16 mg 68 73 141 (27.3%)
24 mg 165 162 327 (63.4%)
Total 255 (49.4%) 261 (50.6%) 516 (100%)
![Page 23: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/23.jpg)
23
ADHERENCE STRATEGIES
![Page 24: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/24.jpg)
24
Potential Adherence Measures• Observed dosing• Pill counts• Biologic marker• Electronic monitoring• Self report• Plasma or urine drug concentrations
![Page 25: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/25.jpg)
25
PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS
Lessons Learned in the CTN
![Page 26: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/26.jpg)
26
0053 Achieving Cannabis Cessation - Evaluating N-Acetylcysteine Treatment (ACCENT)
• The primary objective is to evaluate impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults.
• Medication adherence will be assessed using self-report, blister pack pill counts, and urine riboflavin testing.
![Page 27: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/27.jpg)
27
0052 Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
![Page 28: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/28.jpg)
28
0052 Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
• The primary objective is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge.
• MEMS, pill count, and participant self-report of medication adherence will be collected.
• Urine samples will be shipped to a central lab, and samples from the buspirone group will be assayed for buspirone and/or its metabolite.
![Page 29: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/29.jpg)
29
MEMS• The Medication Event Monitoring System, (MEMS) is a
medication bottle cap with a microprocessor that records the occurrence and time of each bottle opening.
![Page 30: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/30.jpg)
30
INCLUSION/EXCLUSION STRATEGIES
![Page 31: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/31.jpg)
31
Enrollment Criteria• More restrictive
– Increase safety– Possibly increase likelihood of effect
• Less restrictive– Increase generalizability– Interventions found efficacious in clinical trials often
fail in real world
![Page 32: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/32.jpg)
32
PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS
Lessons Learned in the CTN
![Page 33: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/33.jpg)
33
Exclusions 0027 START
• ALT or AST values > 5 times the upper limit of normal
• Known diagnosis of acute psychosis, severe depression or imminent suicide risk
• Poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility
![Page 34: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/34.jpg)
34
Exclusions 0052 BRAC• Medical or psychiatric condition that, in the
judgment of the study physician, would make study participation unsafe or which would make treatment compliance difficult. Medical conditions that may compromise participant safety or study conduct include, but are not limited to: – AIDS – liver function tests greater than 3X upper limit of normal – serum creatinine greater than 2 mg/dL
• Psychiatric disorder requiring continued treatment with a psychotropic medication
![Page 35: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/35.jpg)
35
Potential Behavioral Platforms• Medications alone not expected to be fully
efficacious for SUD
• More intensive behavioral intervention– Could overwhelm medication effects– Could provide sufficient support and/or synergy to
allow medication to work• Less intensive behavioral intervention
– Less likely to overwhelm medication effects– May not hold patients in treatment sufficiently to
allow medication to work
![Page 36: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/36.jpg)
36
PRIOR MEDICATION ASSISTED TREATMENT PROTOCOLS
Lessons Learned in the CTN
![Page 37: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/37.jpg)
37
Behavioral Interventions from CTN MAT Trials
• Bup Taper and START – Counseling as usual
• OROS-methylphenidate ADHD/SUD– CBT (highly efficacious)
• ACCENT– compliance enhancement (CE) and contingency
management (CM)
![Page 38: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/38.jpg)
38
CTN 0028 OROS-Methylphenidate ADHD/SUD
Riggs et al., 2011
![Page 39: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/39.jpg)
39
SAFETY MONITORING
![Page 40: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/40.jpg)
40
Safety Monitoring
• Data Safety Monitoring Board– Established for CTN MAT Trials
• Plan to assess adverse events and serious adverse events
• Laboratory monitoring– e.g., liver tests, glucose, CBC
• Cardiac monitoring– ECG
![Page 41: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/41.jpg)
41
Recap / Highlights
• Designing MAT trials involves numerous decision points and trade-offs
• MAT trials conducted in CTN can provide considerable guidance in making these decisions for design of future MAT trials
![Page 42: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/42.jpg)
42
Q&A – Questions / Comments
Alternatively, questions can be directed to the presenter by sending an email to [email protected].
![Page 43: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/43.jpg)
43
References• Saxon et al., Buprenorphine/Naloxone and methadone
effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence 128:71-76, 2013.
• Riggs et al., Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention deficit/hyperactivity disorder and substance use disorders. Journal of the American Academy of Child & Adolescent Psychiatry 50:903-914, 2011.
• Ling et al., Buprenorphine tapering schedule and illicit opioid use. Addiction 104:256-265, 2009.
![Page 44: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/44.jpg)
44
Survey Reminder
Upcoming Webinar
The NIDA CCC encourages all to complete the survey issued to participants directly following this webinar session. Watch for the email notification!
Also, please visit the Training Suggestion Box to post general comments: https://www.surveymonkey.com/s/CTNTrainingSuggestionBox
Social Media – Using Social Media as a Clinical Trials Research Tool
Wednesday, August 21, 20131:00 pm to 2:00 pm ET
![Page 45: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/45.jpg)
45
A copy of this presentation will be available electronically after this session.
http://ctndisseminationlibrary.org
![Page 46: DEVELOPING MEDICATION ASSISTED TREATMENT (MAT) PROTOCOLS](https://reader038.vdocuments.site/reader038/viewer/2022102714/568167e5550346895ddd5165/html5/thumbnails/46.jpg)
46
Thank you for participating.NIDA CTN Web Seminar Series